Executive Summary
Scancell Holdings plc, which was founded in 1997 as a spin-out from the University of Nottingham, has secured ?8.7 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody
